Recombinant erythropoietin for zidovudine-induced anemia in AIDS.
Recombinant erythropoietin (Epogen, Amgen Pharmaceuticals; Procrit, Amgen Pharmaceuticals, distributed by Ortho Biotech) is approved for use in anemia associated with HIV infection and treatment. The recommended starting dose is 100 IU/kg iv or sc 3 times per week. Current evidence suggests that anemia in zidovudine-treated patients may be a result of insufficient quantities of erythropoietin, bone marrow unresponsiveness to the hormone, or HIV infection. Among patients receiving zidovudine, a review of the available data suggests that baseline serum erythropoietin concentrations may aid in predicting the response to exogenous hormone administration.
Department of Preventive Medicine, College of Medicine, University of Iowa, Iowa City 52242, USA.
A K
AK
Kuehl
S E
SE
Noormohamed
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects*
D011994:Recombinant Proteins; D004921:Erythropoietin; D015215:Zidovudine